James Freeman
Impact in
- Cancer Research top 5%
- Cancer Genomics and Diagnostics
- Oncology top 10%
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
- Oncology 11
- Cancer Cells and Metastasis 9
- CAR-T cell therapy research 3
- Cutaneous Melanoma Detection and Management 3
- Cancer Immunotherapy and Biomarkers 1
-
- Immunotherapy and Immune Responses 5
- Co-authors
- Elin S. Gray (11 shared papers)Mel Ziman (11 shared papers)Michael Millward (8 shared papers)Anna Reid (6 shared papers)Tarek Meniawy (4 shared papers)Muhammad A. Khattak (5 shared papers)Michelle R. Pereira (5 shared papers)Chris Lomma (2 shared papers)
- Journals
- Cancers (2 papers)Oncotarget (2 papers)British Journal of Cancer (1 paper)Journal of Translational Medicine (1 paper)JCO Precision Oncology (1 paper)
- Partner nations
- AustraliaUnited States
In The Last Decade
James Freeman
11 papers receiving 661 citations
Peers
Comparison fields: 5 of 57
- Cancer Research 375
- Oncology 417
- Immunology 158
- Ophthalmology 51
- Molecular Biology 268
Countries citing papers authored by James Freeman
This map shows the geographic impact of James Freeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Freeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Freeman more than expected).
Fields of papers citing papers by James Freeman
This network shows the impact of papers produced by James Freeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Freeman. The network helps show where James Freeman may publish in the future.
Co-authors
The 25 scholars most cited alongside James Freeman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 260 | |
| 2 | 2014 | 84 | |
| 3 | 2019 | 67 | |
| 4 | 2012 | 49 | |
| 5 | 2020 | 48 | |
| 6 | 2017 | 47 | |
| 7 | 2014 | 45 | |
| 8 | 2018 | 43 | |
| 9 | 2019 | 15 | |
| 10 | 2021 | 9 | |
| 11 | DETECTION OF CHROMOSOMAL ABERRATIONS ASSOCIATED WITH PROGNOSIS OF UVEAL MELANOMA USING CIRCULATING TUMOUR CELLS | 2017 | 1 |
About James Freeman
James Freeman is a scholar working on Oncology, Immunology, Molecular Biology, Cancer Research and Ophthalmology, having authored 11 papers that have together received 668 indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (9 papers), Immunotherapy and Immune Responses (5 papers), Cancer Genomics and Diagnostics (4 papers), CAR-T cell therapy research (3 papers), Cutaneous Melanoma Detection and Management (3 papers), Ocular Oncology and Treatments (2 papers), Single-cell and spatial transcriptomics (1 paper) and Cancer Immunotherapy and Biomarkers (1 paper). The work is most often cited by research in Cancer Research (375 citations), Oncology (417 citations), Immunology (158 citations), Ophthalmology (51 citations) and Molecular Biology (268 citations). James Freeman has collaborated with scholars based in Australia and United States. Frequent co-authors include Elin S. Gray, Mel Ziman, Michael Millward, Anna Reid, Tarek Meniawy, Muhammad A. Khattak, Michelle R. Pereira, Chris Lomma, Johnny Lo and Michael Millward. Their work appears in journals such as Cancers, Oncotarget, British Journal of Cancer, Journal of Translational Medicine and JCO Precision Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.